Subjects over the age 60 with sustained sitting diastolic pressures of 95-115 mm Hg were randomised to a regime based on bisoprolol (n ‫؍‬ 368) or nifedipine retard (n ‫؍‬ 379) for 24 weeks. The goal diastolic pressure was р90 mm Hg and to achieve this, double-blind medication could be doubled (5/10 mg bisoprolol, 40/80 mg nifedipine retard) or hydrochlorothiazide 25 mg (unblinded) could be added to the higher dose. In an intention-to-treat analysis, 309 subjects in both the bisoprolol and nifedipine retard treated group provided at least a baseline and a second quality of life assessment (82%). An excess of symptoms was observed in the nifedipine group for oedema of the legs, nocturia, constipation, racing heart and heart thumping. Fewer patients reported wheeze in the nifedipine group. For
Introduction
The quality of life (QOL) of patients on antihypertensive treatment is important in many ways. Firstly, measures of quality of life reflect physical and psychological well-being and activity and these are of premium importance to the patient. Second, quality of life is affected by the nature of the treatment and is closely related to default from treatment and non-compliance with the treatment regime. 1 Nifedipine retard and bisoprolol are both widely prescribed representatives of the dihydropyridine calcium channel blockers and selective beta-blockers respectively. Although these drug groups have been compared in quality of life trials 2-4 the outcome has not been clear. The first trial compared nifedipine gastrointestinal therapeutic system (GITS) with atenolol. 2 Withdrawal rates on nifedipine tended to be high but there was an advantage for nifedipine GITS in the 60% of patients remaining on the drug. This was not confirmed in the intention-to-treat analysis. In the second trial 540 patients were randomised to 6 months treatment with either nifedipine retard, atenolol or cilazapril. 3 Symptomatic complaints and withdrawals increased with nifedipine retard but fatigue was lessened by this drug. Finally a small cross-over trial of 61 patients received 8 weeks of bisoprolol and 8 weeks of nifedipine retard. 4 There was no difference between the drugs in the QOL outcome although the 'on-treatment' analysis suggested a trend in favour of nifedipine in a Health Status Index (HSI). Individual symptoms were not reported in this trial but the overall complaint rate was incorporated in the HSI. 4, 5 However the relative merits of the two drugs have not been established and we report the results of a large trial performed by the European Bisoprolol Trial Investigators to compare bisoprolol with nifedipine retard. 6 It is also widely believed that beta-blockers may have additional benefits in reducing anxiety and tension. Thus several trials have assessed anxiety with beta-blocker treatment using the Symptom Rating Test (SRT) or Profile of Mood States (POMS). This aspect of beta-blocker therapy is also assessed in the present trial.
Male or female patients over 60 years of age suffering from essential hypertension (sitting diastolic blood pressure on placebo at baseline у95 mm Hg and р115 mm Hg) were eligible for inclusion. Previous antihypertensive medication was washed out during 14 days prior to the first administration of active study medication. Informed consent was obtained from all patients prior to any study-related procedures. During the second week of wash-out on no treatment a placebo was given. The randomised double-blind active-treatment period lasted for 6 months and started with low-dose therapy (bisoprolol 5 mg o.d., or nifedipine retard 20 mg b.d.) for 4 weeks. Matching placebos were employed so that all subjects took the same number of tablets. After 4 weeks, they remained on low-dose treatment if diastolic blood pressure had been reduced to р90 mm Hg or they were titrated to the higher doses of study medication (bisoprolol 10 mg o.d., nifedipine retard 40 mg b.d.). After another 4 weeks, patients on high-dose treatment whose diastolic blood pressure continued to be Ͼ90 mm Hg were given unblinded 25 mg of hydrochlorothiazide (HCT), in addition.
Blood pressure measurements (sitting after 5, 6 and 7 min of rest, standing 2, 3 and 4 min after rising) were performed at baseline as well as after 4, 8 and 24 weeks of active treatment.
All measurements were carried out at approximately the same time of day (in the morning prior to the morning dose) using a standard sphygmomanometer. Systolic blood pressure was taken as Korotkoff phase I and diastolic blood pressure as Korotkoff phase V sounds.
Adverse events which were volunteered by subjects or observed by the investigators were recorded, regardless of whether or not a causal relationship with the study medication was assumed. Adverse events were also assessed as to their intensity (mild, moderate or severe). Safety laboratory parameters (haemoglobin, leucocytes, differential white cell count, ASAT ALAT, ␥-GT, glucose, total cholesterol, triglycerides, creatinine, electrolytes) and standard 12-lead ECG recordings at rest were performed at the beginning and at the end of the study. Furthermore, investigators and patients were asked about the tolerability of the study medication. All study medication (placebo, bisoprolol, nifedipine retard) was provided as capsules of identical size, colour and shape.
Investigators were based in Austria, Italy, Germany, Netherlands, Poland, Spain, Switzerland and the UK. The study was conducted in accordance with the Declaration of Helsinki as amended in Tokyo, Venice and Hong Kong and good clinical practice (GCP) guidelines. The trial protocol was approved by independent ethics committees of each participating country.
Quality of life measurement
The English version of the questionnaire was translated into Dutch, German, Italian, Polish and Spanish and back-translated by someone who had not seen the original English version. The translation and back-translation was repeated until an acceptable match was obtained to the original. The translations were tested with patients to ensure that they were acceptable to, and understood by, the average person.
The interviewers were all trained by the investigators in dedicated sessions. In the trial the QOL questionnaire was administered by the trained interviewers in a quiet location prior to having blood pressure or other measurements made. The questionnaire consisted of the following sections.
(a) Following sections of the Sickness Impact Profile (SIP) 7 Social Interaction: describes the effects of poor health on relationships with family and friends, and enjoyment of social activities. Homework: describes the effects of poor health on housework, and other primarily physical activities related to looking after the home. Sleep and Rest: describes the effect of poor health on daytime and night-time rest.
Each section includes a set of statements which are individually read to the patient. They respond if they agree with the statement, and also if it is due to their health. High scores indicate worse quality of life. The patients are asked to write different symbols next to numbers 1 to 9. The number of correct responses are counted over 90 sec. This is a test of cognitive functioning, namely psychomotor performance, attention and integration.
(c) Symbol copying
This was adopted from the Digit Symbol Substitution Test. The patients are asked to copy as many of a random series of 240 symbols for a period of 90 sec. The number of correct copies informs more on motor speed than cognitive functioning. This assesses the performance of everyday memory tasks as reported by the subject. Twenty-five items were scored on a 5-point scale. A high score indicates less good memory. 10 This is a 65-item scale consisting of six subscales: tension/anxiety, depression/dejection, anger/ hostility, vigour/activity, fatigue/inertia and confusion/bewilderment. Patients rate each item on a five-point scale. A high score indicates a worse quality of life except for vigour/activity.
(f) Profile of Mood States (POMS)

(g) Symptom assessment
5 Thirty-four symptoms were assessed including those associated with hypertension and those occurring as side effects of treatment. Thirty-four were assessed in men and 32 in women. The patients rated their symptoms on a five-point scale according to how much the symptom had bothered them in the past week, namely not at all, a little, moderately, quite a bit and extremely. Symptoms were also categorised as present (bothered them moderately, quite a bit or extremely) or absent (present, not at all or a little). The latter categories were employed to provide a complaint rate giving the percentage of symptoms reported.
(h) Health Status Index (HSI)
This varies between a theoretical high of 1.0 (when perfectly well) to zero when dead. The HSI is computed from answers to the SIP and other questions and modified according to the symptom complaint rate. 5, 11 Quality control of the questionnaires was performed centrally by the Epidemiology Research Unit based at the Hammersmith Hospital Campus. One centre was removed from the study as the questionnaires were given to the patients to complete and the information was not collected by an interviewer.
Statistical methods
Efficacy variables were primarily analysed using the intention-to-treat (ITT) approach. Additionally, a supportive per-protocol analysis was carried out. Differences between medications regarding withdrawal rates were assessed by Fisher's exact test. When assessing changes between two time points, data in excess of 3 standard deviations in either direction were excluded.
Changes in QOL measures were determined between baseline (0) and 8 weeks, between baseline and 24 weeks and between baseline and the last available questionnaire. The analyses to be presented include the 0 to 8-week intention to treat analysis and the 0 -last available analysis. The latter was very similar to the 0 to 24-week analysis but included data from withdrawing patients. The change in QOL summary statistics were compared using an unpaired t-test with logarithmic transformation as required. The change in symptoms was assessed by chi-squared tests.
The effect size was calculated for certain variables. This is the difference between the drugs in the Journal of Human Hypertension change in a particular variable, divided by the pooled standard deviation at baseline.
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Results
A total of 771 patients were enrolled into the study. During the prephrase 24 patients were withdrawn, 747 patients were randomised by 60 trial centres in eight European countries. The study was completed by 614 patients. Dropouts from active treatment for occurrence of adverse events refer to 74 patients (bisoprolol: n = 23; nifedipine: n = 51). All 747 patients randomised took at least one dose of active medication and were included in the analysis of safety (bisoprolol: n = 368; nifedipine: n = 379). Patient characteristics and previous antihypertensive medication were very similar in the two treatment groups. 6 Blood pressure averaged 167/101 and 169/102 mm Hg in the bisoprolol and nifedipine groups at baseline. After 24 weeks the blood pressures were 149/86 and 148/86 mm Hg respectively. 6 In the intention-to-treat analysis of 721 patients, 490 patients were on treatment with low dose (bisoprolol: n = 229/64.1%; nifedipine: n = 261/71.7%), 145 with high dose (bisoprolol: n = 75/21.0%; nifedipine: n = 70/19.2%) and 86 with high dose plus hydrochlorothiazide (bisoprolol: n = 53/14.9%; nifedipine: n = 33/9.1%) at their individual study end.
Adverse events
Seventy-four adverse drug reactions led to withdrawal, 51 in the nifedipine group (13.5%) and 23 in the bisoprolol group (6.3%, P Ͻ 0.001). As expected nifedipine treatment led to oedema (14 subjects), flushing (10) and headache (5). The corresponding results for bisoprolol were three, one and one respectively. Bisoprolol reduced palpitations (zero compared with four) and was not associated with any serious asthmatic reactions, although change was reported by two patients (compared to none).
Baseline characteristics of patients providing two or more assessments of quality of life
Eighty-four percent of patients receiving bisoprolol (309) and 82% of those receiving nifedipine (309) completed two or more quality of life interviews. Table 1 gives the baseline characteristics for these patients. Average age was 68 years with a range of 59-90 years. There were no statistically significant differences at baseline between the two randomised groups. Table 2 gives the changes in the quality of life scores between 0 and 8 weeks and between the baseline and the last available questionnaire following randomisation. The second analysis allows the capture of information on those who withdrew. However, these results are almost identical to those for the change between 0 and 24 weeks as 281 on bisoprolol completed a 24-week questionnaire and 273 on nifedipine. All analyses were intention-to-treat.
Between baseline and 8 weeks the complaint rate fell on both bisoprolol and nifedipine. The two The intention-to-treat changes between 0 and 24 weeks confirmed the changes between baseline and last available questionnaire in tension-anxiety (P = 0.001), anger/hostility (P = 0.018), vigour (P = 0.003) but not confusion (P = 0.125). A per protocol 0 to 24-week analysis also confirmed these results. The changes in total complaint rate were not statistically significantly different, either in the O-LA analysis (Table 2 ) nor the 0 to 24-week intention-to-treat analysis (a 3.09 unit reduction with bisoprolol compared with a 2.02 unit reduction with nifedipine, P = 0.151). Table 3 gives the changes in symptoms that covered the adverse drug reactions leading to withdrawal, namely oedema, flushing, headache, palpitations, itching and wheezing; and two other symptoms, statistically significant at the 1% level, constipation, and nocturia. Nifedipine was associated (P Ͻ 0.01) with a statistically significant excess P values assess between drug differences; R, Retard.
Journal of Human Hypertension of oedema, constipation, and nocturia and, compatible with the known action of beta adrenoceptor blocking drugs, bisoprolol tended to reduce (P Ͻ 0.05) heart thumping and racing heart and to be associated with wheezing.
Discussion
The present trial studied over 600 patients followed for 24 weeks and is broadly in agreement with a trial that compared 182 patients on atenolol with 179 on nifedipine retard for a 6-month period. 3 Both trials showed an excess of symptomatic complaints on nifedipine retard leading to a higher discontinuation rate on nifedipine. However, most importantly, in the smaller trial atenolol did not influence psychological well-being although the POMS was also employed in assessment. Bisoprolol is more lipophilic than atenolol 13 and therefore could be expected to enter the central nervous system (CNS) more effectively. However, propranolol is even more lipophilic and produces an excess of symptoms, 14, 15 supposedly due to CNS penetration. Bisoprolol is notable for its ␤ 1 selectivity 13 and this may provide a clue as to how it reduces tension, anxiety, anger and confusion. It has been stated that 'alterations in mood and thought appear to be caused more often by other beta-blockers than by bisoprolol'. 13 This observation may have arisen from beneficial effects of bisoprolol on anxiety, tension and confusion. In randomised quality of life studies atenolol has produced results equivalent to angiotensin-converting enzyme (ACE) inhibitors, verapamil, and a diuretic. 1 In a study comparing atenolol with the nifedipine gastrointestinal therapeutic system (GITS); where release of drug is more gradual and 24-h action is provided with one dose, a per protocol analysis suggested an advantage from nifedipine GITS but the intention-to-treat analysis did not confirm this. 2 The difference between the two analyses is assumed to be due to the exclusion of withdrawals from the per protocol analysis. Nevertheless it is probable that long-acting formulations of nifedipine smooth out the peak and trough plasma concentrations and have an advantage over nifedipine retard. However, a recent comparison of nifedipine GITS with the longer acting dihydropyridine calcium channel blocker, amlodipine, suggested advantages in the overall measures of QOL and vitality for nifedipine GITS, albeit with more positive effects on cognitive functioning in the amlodipine group. 16 A randomised QOL trial is required comparing bisoprolol, atenolol and longacting nifedipine. Owing to differential withdrawal the present analysis relies mainly on the comparison of baseline with the last available information in an intention-to-treat analysis.
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The randomised cross-over trial of de Hoon and colleagues 4 was similar in certain respects to the present trial but only obtained QOL results in 61 patients studied for 8 weeks. The present trial demonstrates that the benefits of bisoprolol were not apparent at 8 weeks. De Hoon et al 4 employed the Bulpitt and Fletcher questionnaire 5 and the Symptom Rating Test (SRT) 17 as a measure of psychological well-being and failed to determine a reduction in anxiety with bisoprolol. They did not report the individual symptoms incorporated in the Bulpitt and Fletcher questionnaire but listed 17 adverse events on bisoprolol against 10 on nifedipine retard. The latter did not include oedema, flushing or headache. Three patients dropped out whilst on nifedipine retard and three on bisoprolol. The disagreement between the result of the two trials may be due to the relatively small numbers being followed for 8 weeks in the de Hoon study. Similarly the randomised cross-over trial of Vanmolkot et al 18 employed the Bulpitt and Fletcher questionnaire and the SRT. The authors compared bisoprolol with bendrofluazide, found no differences, but only studied patients for 8 weeks.
In a trial comparing dilevalol with bendrofluazide in the elderly hypertensive over 6 months 19 the Profile of Mood States was employed as in the present trial. The falls in tension-anxiety and depressiondejection on dilevalol were 1.06 and 1.31 units respectively with significance levels of 0.12 and 0.09 when compared with bendrofluazide. These changes are similar to those observed in the present study and may be due to the fact that dilevalol is also a beta-blocker. However, dilevalol is a non-specific beta-blocker with some alpha-blocking activity and beta-adrenergic peripheral vasodilating capacity. The drug has been withdrawn owing to hepatotoxicity. 20 Table 4 gives the effect sizes for nine trials in hypertensive patients where anxiety has been measured using the Symptom Rating Test (SRT) or tension/anxiety using the Profile of Mood States (POMS). The effect size allows a direct comparison of the results in different trials. One trial had a small effect size of 0.32 and suggested that propranolol did not reduce anxiety. 15 Three trials compared atenolol with an ACE inhibitor and, although atenolol always tended to reduce anxiety more than the ACE inhibitors (effect sizes 0.02 to 0.17), no effect size was substantial. Similarly the effect size for dilevalol compared to bendrofluazide (0.21) was small. In the present study the effect size for anxiety in favour of bisoprolol was of a similar order of magnitude (0.23) to that observed in the comparison of dilevalol with bendrofluazide and suggests a real but small benefit in favour of these beta-blockers. As pointed out above, these benefits were not apparent after 8 weeks of treatment.
Confusion/bewilderment POMS scores did not differ in the dilevalol/bendrofluazide trial, 18 nor in the atenolol/cilazapril/nifedipine trial. 3 Nevertheless dilevalol treatment was significantly better than bendrofluazide when assessed by the objective Digit Symbol Substitution and Symbol Copying tests. In the present trial objective tests of cognitive func-tioning did not reveal any differences between bisoprolol and nifedipine retard nor did subjective evaluation of memory and attention. However there was some evidence for a greater improvement in confusion/bewilderment on bisoprolol compared to nifedipine retard. Although of borderline significance (P = 0.04) two other trials have reported a subjective cognitive problem with nifedipine retard. These trials assessed cognitive function with the Symptom Rating Test. 21, 22 One revealed a deterioration with nifedipine retard in comparison with pinacidil, a potassium channel opener, and the second revealed a deterioration with nifedipine retard in comparison with verapamil. Table 4 gives the effect sizes. Small effects (effect sizes 0.32-0.36) were seen when verapamil was compared with nifedipine retard and rilmenidine was compared with methyldopa. Very small effect sizes were observed when verapamil was compared to propranolol (0.14), pinacidil to nifedipine retard (0.18), dilevalol to bendrofluazide (0.13), and bisoprolol to nifedipine retard (0.09-0.13). Atenolol did not differ from captopril, cilazapril or nifedipine retard with respect to cognitive functioning. These data are difficult to interpret but the possibility remains that methyldopa and nifedipine have subtle adverse effects on cognitive function with methyldopa having the greatest impact. This may also be true for propranolol, 15 bendrofluazide [18] [19] and nifedipine GITS. 16 A recent observational study revealed increased white matter changes in patients treated with calcium channel blockers. 26 However a large randomised trial of active treatment against placebo in the management of isolated systolic hypertension (the Syst-Eur trial), revealed that treatment with a calcium blocker, nitrendipine, did not impair cognitive function and tended to reduce the incidence of dementia. 27 In addition, objective measures of cognitive functioning in one randomised trial did not reveal any difference between nifedipine retard, atenolol and cilazapril. 3 Whether or not nifedipine retard produces a real decline in cognitive function compared to other treatments is unknown, but treatment with a similar dihydropyridine drug, nitrendipine, is better than placebo in cardiovascular terms 28 and it is probable that the reported subjective effects are reversible on stopping the drug.
We conclude that, in quality of life terms, bisoprolol had advantages over nifedipine retard in symptomatic and psychological well-being. It remains to be determined whether or not bisoprolol has advantages over other beta-blockers or long-acting preparations of nifedipine.
